The Influence of Adiposity Levels on the Relation between Perfluoroalkyl Substances and High Depressive Symptom Scores in Czech Adults
Author:
Neto Geraldo1ORCID, Bobak Martin23, Gonzalez-Rivas Juan P.145ORCID, Klanova Jana2
Affiliation:
1. International Clinical Research Center (ICRC), St. Anne’s University Hospital (FNUSA), 65691 Brno, Czech Republic 2. Research Centre for Toxic Compounds in the Environment (RECETOX), Faculty of Science, Masaryk University, 62500 Brno, Czech Republic 3. Research Department of Epidemiology and Public Health, University College London, London WC1H 9BT, UK 4. Department of Global Health and Population, Harvard TH Chan School of Public Health, Harvard University, Boston, MA 02138, USA 5. Foundation for Clinic, Public Health, and Epidemiology Research of Venezuela (FISPEVEN INC), Caracas 3001, Venezuela
Abstract
The extensive use and bioaccumulation of Perfluoroalkyl Substances (PFAS) over time raise concerns about their impact on health, including mental issues such as depression. This study aims to evaluate the association between PFAS and depression. In addition, considering the importance of PFAS as an endocrine disruptor and in adipogenesis, the analyses will also be stratified by body fat status. A cross-sectional study with 479 subjects (56.4% women, 25–89 years) was conducted. Four PFAS were measured: perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), and perfluorooctane sulfonate (PFOS). The Poisson regression model was applied using robust error variances. The fully adjusted model included age, sex, educational level, income, smoking, physical activity, body fat percentage, and the questionnaire to assess depression. The prevalence of depression and high body fat was 7.9% and 41.1%, respectively. Only PFOA was significantly associated with depression in the entire sample (prevalence rate (PR): 1.91; confidence interval (CI95%): 1.01–3.65). However, in the group with normal adiposity, PFOA (3.20, CI95%: 1.46–7.01), PFNA (2.54, CI95%: 1.29–5.00), and PFDA (2.09, CI95%: 1.09–4.00) were also significant. Future research should investigate the role of obesity as well as the biological plausibility and possible mechanisms increasing the limited number of evidences between PFAS and depression.
Funder
Horizon 2020 European Regional Development Fund
Subject
Chemical Health and Safety,Health, Toxicology and Mutagenesis,Toxicology
Reference56 articles.
1. EFSA Panel on Contaminants in the Food Chain (CONTAM), Knutsen, H.K., Alexander, J., Barregard, L., Bignami, M., Bruschweiler, B., Ceccatelli, S., Cottrill, B., Dinovi, M., and Edler, L. (2018). Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food. EFSA J., 16, e05194. 2. “Forever Chemicals”: Forever Altering the Legal Landscape;Diaz;Belmont Law Rev.,2019 3. Perfluorinated compounds—Exposure assessment for the general population in Western countries;Fromme;Int. J. Hyg. Environ. Health,2009 4. Perfluoroalkyl and polyfluoroalkyl substance exposure and association with sex hormone concentrations: Results from the NHANES 2015–2016;Xie;Environ. Sci. Eur.,2021 5. Di Law, H., Armstrong, B., D’Este, C., Randall, D., Hosking, R., Lazarevic, N., Trevenar, S., Smurthwaite, K., Lal, A., and Lucas, R. (2021). PFAS Health Study, Australian National University.
|
|